QRxPharma Ltd.  

(Public, ASX:QRX)   Watch this stock  
Find more results for QRX
0.0750
0.0000 (0.00%)
Jul 31 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.08 - 0.08
52 week 0.07 - 1.25
Open 0.08
Vol / Avg. 15,400.00/278,268.00
Mkt cap 12.31M
P/E     -
Div/yield     -
EPS -0.07
Shares 164.12M
Beta     -
Inst. own     -
Aug 27, 2014
Preliminary 2014 QRxPharma Ltd Earnings Release Add to calendar
Jul 9, 2014
Extraordinary Shareholders Meeting
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -827.74% -247.91%
Operating margin -882.10% -262.59%
EBITD margin - -264.71%
Return on average assets -67.16% -53.85%
Return on average equity -78.00% -71.60%
CDP Score - -

Address

Level 1, 194 Miller Street
NORTH SYDNEY, NSW 2060
Australia
+61-2-94928021 (Phone)
+61-2-89200314 (Fax)

Description

QRxPharma Limited is a commercial-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management. The Company�s complementary pain management product formulations- in both early and late stage clinical development, which include: MOXDUO IR, an immediate release oral capsule for acute pain; MOXDUO CR, a controlled release oral tablet chronic pain; and MOXDUO IV, an intravenous formulation for moderate to severe hospital-based pain. The Company is developing Dual Opioid formulation for treating patients with moderate to server acute or chronic pain. The Company�s Dual Opioid portfolio includes three complementary products: Q8003, an immediate-release oral capsule for acute pain; Q8011, a controlled-release oral tablet (with abuse deterrent and tamper resistant features) for chronic pain; Q8012, an intravenous formulation for moderate to severe pain secondary to hospital based procedures.

Officers and directors

Edward M. Rudnic Ph.D. Chief Executive Officer
Chris J Campbell Chief Financial Officer, Company Secretary
Age: 48
M. Janette Dixon Vice President - Global Business Development
Peter C. Farrell Ph.D. Non-Executive Chairman of the Board
Age: 71
R. Peter Campbell Non-Executive Director
Gary W. Pace Ph.D. Non-Executive Director
Age: 66
Michael A. Quinn Non-Executive Director
Age: 65